VIR241220C12500
- 0.05
- 0.000.00%
Vir Biotechnology Newsroom
J.P. Morgan Sticks to Their Hold Rating for Vir Biotechnology (VIR)
Leerink Partners Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $18
HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $110 Price Target
TD Cowen Maintains Vir Biotechnology(VIR.US) With Buy Rating
A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $10 to $26
TD Cowen Keeps Their Buy Rating on Vir Biotechnology (VIR)
Vir Biotechnology: Hold Rating Amidst Promising HDV Study Results and Future HBV Developments
Vir Biotechnology Analyst Ratings
Barclays Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $26
J.P. Morgan Maintains Vir Biotechnology(VIR.US) With Hold Rating, Maintains Target Price $13
Analysts Conflicted on These Healthcare Names: Vir Biotechnology (VIR) and Moderna (MRNA)
HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $110 Price Target
Vir Biotechnology's Promising Hepatitis Programs and Strategic FDA Alignment Justify Buy Rating
Barclays Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $26
A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $10 to $19
A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $10 to $19
Vir Biotechnology Analyst Ratings
Needham Reiterates Buy on Vir Biotechnology, Maintains $19 Price Target
Analysts Have Conflicting Sentiments on These Healthcare Companies: Corvus Pharmaceuticals (CRVS), Vir Biotechnology (VIR) and Cooper Co (COO)
Vir Biotechnology Analyst Ratings